P-glycoprotein potentiates CYP3A4-mediated drug disappearance during Caco-2 intestinal secretory detoxification

Lauretta M S Chan1, Anne E Cooper, Adam L J Dudley

  • 1Institute for Cell and Molecular Biosciences, University of Newcastle Medical School, Newcastle upon Tyne NE2 4HH, UK.

Journal of Drug Targeting
|December 29, 2004
PubMed

Insights

Drugs interacting with P-glycoprotein (Pgp) can enhance CYP3A4-mediated drug metabolism in the intestines. This study shows Pgp potentiates CYP3A4 activity, aiding in intestinal drug detoxification.

Area of Science:

  • Pharmacology
  • Drug Metabolism
  • Gastrointestinal Physiology

Background:

  • The intestinal epithelium plays a crucial role in drug absorption and metabolism.
  • P-glycoprotein (Pgp) and Cytochrome P450 3A4 (CYP3A4) are key players in drug efflux and metabolism, respectively.
  • Understanding their interplay is vital for predicting drug disposition and efficacy.

Purpose of the Study:

  • To investigate whether drugs interacting with P-glycoprotein (Pgp) can enhance the activity of Cytochrome P450 3A4 (CYP3A4).
  • To determine the role of Pgp in the intestinal detoxification of co-substrates.

Main Methods:

  • Utilized human intestinal Caco-2 cell monolayers.
  • Assessed CYP3A4 activity by measuring 6beta-hydroxytestosterone production from testosterone.
  • Investigated the transport and disappearance of CYP3A4 and/or Pgp substrates (testosterone, vinblastine, erythromycin) in the presence and absence of digoxin (a Pgp inhibitor).

Main Results:

  • CYP3A4 activity (testosterone metabolism) was increased by 1,25(OH)2D3 treatment but unaffected by digoxin.
  • Digoxin significantly reduced the secretory transport and basolateral disappearance of Pgp/CYP3A4 co-substrates (vinblastine, erythromycin).
  • Testosterone, a CYP3A4-only substrate, showed no change in transport or disappearance with digoxin, confirming digoxin's effect was Pgp-mediated.

Conclusions:

  • P-glycoprotein (Pgp) potentiates CYP3A4-mediated drug disappearance.
  • This interaction facilitates intestinal secretory detoxification of drugs that are co-substrates for both Pgp and CYP3A4.
  • The findings highlight a significant drug-drug interaction mechanism at the intestinal level.

Related Concept Videos

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Drug Absorption: Factors Affecting GI Absorption01:19

Drug Absorption: Factors Affecting GI Absorption

The process of oral drug absorption can be influenced by several factors. Weakly acidic drugs tend to be absorbed more readily from the stomach due to their nonionized state. However, absorption may be less efficient in the upper intestine, where drugs are often ionized. Interestingly, despite the stomach's apparent advantage for drug absorption, its mucous layer can hinder diffusion. Its surface area is also smaller than the intestine's, which can further slow down the absorption rate.
In...